Rashna Sharmin Jessy
- Designation: BNS Haji Mohsin Sick Bay
- Country: Bangladesh
- Title: Comparative Study of Oral Isotretinoin Versus
Weekly Azithromycin in the Treatment of Nodulocystic Acne
Abstract
Acne vulgaris is a common dermatological disorder affecting pilosebaceous units and accounts for a significant proportion of dermatology consultations worldwide. Nodulocystic acne represents a severe form requiring systemic therapy. Oral isotretinoin is considered the gold standard, while azithromycin is used as an alternative due to better tolerability.
To compare the efficacy, safety, and patient satisfaction of oral isotretinoin versus weekly pulse azithromycin in the treatment of nodulocystic acne.
This experimental study was conducted at the Department of Dermatology, Combined Military Hospital (CMH), Dhaka, from April 2023 to September 2023. A total of 108 patients with nodulocystic acne were enrolled and divided into two groups (54 patients each). The isotretinoin group received oral isotretinoin (0.5 to 1 mg kg day) for 12 weeks. The azithromycin group received azithromycin 500 mg daily for 3 consecutive days per week for 12 weeks. Patients were evaluated at baseline and at 4, 8, and 12 weeks using the Investigator’s Global Assessment (IGA) scale. Treatment response, patient satisfaction, safety, and compliance were recorded.